Kenneth Hillan
Director/Board Member chez SANGAMO THERAPEUTICS, INC.
Fortune : 72 966 $ au 31/03/2024
Profil
Kenneth J.
Hillan is an Independent Director at Sangamo Therapeutics, Inc. and Zymeworks BC, Inc. He is a former CEO, Director & President-R&D Division at Achaogen, Inc., an Independent Director at Relypsa, Inc. and Zymeworks, Inc., and SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. He was also a Member of Roche Group.
Hillan holds a doctorate degree from the University of Glasgow School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/07/2023 | 74 688 ( 0,02% ) | 39 734 $ | 31/03/2024 | |
| 01/06/2023 | 49 600 ( 0,02% ) | 33 232 $ | 31/03/2024 | |
ZYMEWORKS INC.
-.--% | 11/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Kenneth Hillan
| Sociétés | Poste | Début |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Director/Board Member | 11/09/2020 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Director/Board Member | 03/02/2017 |
Anciens postes connus de Kenneth Hillan
| Sociétés | Poste | Fin |
|---|---|---|
| ZYMEWORKS INC. | Director/Board Member | 08/02/2024 |
| 23ANDME HOLDING CO. | Corporate Officer/Principal | 08/08/2023 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Corporate Officer/Principal | 01/06/2021 |
| ACHAOGEN | Chief Executive Officer | 04/04/2019 |
| RELYPSA INC | Director/Board Member | 01/09/2016 |
Formation de Kenneth Hillan
| University of Glasgow School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| 23ANDME HOLDING CO. | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
